UBS Group restated their buy rating on shares of Victrex (LON:VCT) in a research report report published on Thursday morning, investing.thisismoney.co.uk reports. They currently have a GBX 3,200 ($41.81) price target on the stock, down from their previous price target of GBX 3,600 ($47.04).
Several other equities research analysts also recently weighed in on the stock. Morgan Stanley downgraded shares of Victrex to an underweight rating and dropped their target price for the stock from GBX 2,500 ($32.67) to GBX 2,300 ($30.05) in a research report on Friday, October 12th. Liberum Capital reissued a buy rating on shares of Victrex in a research report on Tuesday, October 16th. Peel Hunt reissued an add rating on shares of Victrex in a research report on Tuesday. Finally, Barclays reissued an underweight rating and issued a GBX 2,420 ($31.62) target price on shares of Victrex in a research report on Wednesday. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of GBX 2,527.73 ($33.03).
Shares of VCT traded up GBX 48 ($0.63) during midday trading on Thursday, hitting GBX 2,342 ($30.60). The company had a trading volume of 189,454 shares, compared to its average volume of 274,177. Victrex has a 52 week low of GBX 1,826 ($23.86) and a 52 week high of GBX 2,772 ($36.22).
In other news, insider Richard Armitage bought 1,010 shares of the firm’s stock in a transaction on Wednesday, December 5th. The stock was purchased at an average price of GBX 2,318 ($30.29) per share, for a total transaction of £23,411.80 ($30,591.66). In the last 90 days, insiders acquired 1,019 shares of company stock valued at $2,367,396.
Victrex plc, through its subsidiaries, manufactures and sells polymers worldwide. It operates through two segments, Victrex Polymer Solutions and Invibio Biomaterial Solutions. The company offers VICTREX PEEK polymer materials; and biomaterial solutions for use in spine, dental, trauma, knee, cardiovascular, and orthopedic applications.
See Also: Relative Strength Index
Receive News & Ratings for Victrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Victrex and related companies with MarketBeat.com's FREE daily email newsletter.